A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma
Study Details
Study Description
Brief Summary
This is a study to evaluate the efficacy and safety of TQB2450 injection combination with Intensity-modulated Radiotherapy in patients with inoperable locally recurrent nasopharyngeal carcinoma.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: TQB2450+Intensity modulated radiotherapy TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day；The total dose of radiotherapy should meet PTVnx: 60Gy/27Fr/2.22Gy, PTVnd: 60-64Gy/27Fr/2.22-2.37Gy, PTV1: 54Gy/27Fr/2.00Gy, once a day, 5 times/week. |
Drug: TQB2450
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Radiation: Intensity modulated radiotherapy
Intensity-modulated conformal radiotherapy (IMRT) is a kind of three dimensional conformal radiotherapy, which requires the dose intensity in the radiation field to be adjusted according to certain requirements.
|
Outcome Measures
Primary Outcome Measures
- Overall response rate (ORR) [up to 48 weeks]
Percentage of participants achieving complete response (CR) and partial response (PR).
Secondary Outcome Measures
- Disease control rate（DCR） [up to 48 weeks]
Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).
- Duration of Response (DOR) [up to 48 weeks]
The time when the participants first achieved complete or partial remission to disease progression.
- Progression-free survival (PFS) [up to 48 weeks]
PFS defined as the time from first dose until the first documented progressive disease (PD) or death from any cause.
- 12-month progression-free survival rate [up to 48 weeks]
12-month PFS defined as the time from first administration until the first documented progressive disease (PD) or death from any cause within 12 months.
- 12-month survival rate [up to 48 weeks]
12-month survival rate defined as the time from first administration to death from any cause within 12 months.
- 24-month survival rate [up to 96 weeks]
24-month survival rate defined as the time from first administration to death from any cause within 24 months.
- Local regional recurrence-free survival (LRRFs) [up to 48 weeks]
The time interval between the patient's first medication and the appearance of local imaging progress.
- Distant metastasis-free survival (DMFS) [up to 48 weeks]
The time interval between the patient's first medication and the appearance of distant metastasis imaging progression or death.
- Overall survival (OS) [up to 96 weeks]
OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
- Understood and Signed an informed consent form; 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; Life expectancy ≥ 3 months; 3. Local recurrence of non-keratinizing nasopharyngeal carcinoma diagnosed by histopathology and/or cytology; Clinical stage: rT2-4N0-3M0 , RII-IVa phase (AJCC eighth edition); 4. The recurrence time is more than 12 months from the end of the first course of radiotherapy, without other systemic or local anti-tumor treatment; 5. At least one measurable lesion (based on RECIST 1.1); 6. Adequate laboratory indicators; 7. No pregnant or breastfeeding women, and a negative pregnancy test.
Exclusion Criteria:
-
- Operable patients with local recurrence, including rT2 (the tumor is confined to the surface of the parapharyngeal space, and the distance from the internal carotid artery > 0.5 cm) and rT3 (the tumor is confined to the bottom wall of the sphenoid sinus, and the distance from the internal carotid artery and cavernous sinus > 0.5 cm) ; 2.Combined diseases and medical history:
-
Accompanied by nasopharyngeal necrosis, radiation brain injury, severe neck fibrosis, or other ≥grade 3 radiation complications, the investigator has assessed that the risk is extremely high and not suitable for radiotherapy;
-
Has other malignant tumors within 3 years;
-
Unalleviated toxicity ≥ grade 1 due to any previous anticancer therapy;
-
Has received major surgical treatment, open biopsy, or obvious traumatic injury within 28 days before the first administration;
-
Long-term unhealed wounds or fractures;
-
Arterial/venous thrombosis events occurred within 6 months, such as cerebrovascular accidents (including temporary ischemic attacks, cerebral; hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism;
-
Has drug abuse history that unable to abstain from or mental disorders;
-
Has any severe and/or uncontrollable disease. 3.Tumor-related symptoms and treatment:
-
Diagnosed local recurrence and received surgery, chemotherapy, radiotherapy or other anti-cancer therapies before first administration;
-
Has received NMPA approved Chinese patent medicines with anti-tumor indications;
-
Has received relevant immunotherapy drugs for PD-1, PD-L1, CTLA-4, etc.;
-
Uncontrollable pleural effusion, pericardial effusion or ascites that still needs to be drained repeatedly (as judged by the investigator); 4.Research and treatment related:
-
Has vaccinated with vaccines or attenuated vaccines within 4 weeks prior to first administration;
-
Have severe hypersensitivity after using monoclonal antibodies;
-
Active autoimmune diseases that require systemic treatment (such as the use of disease-relieving drugs, corticosteroids, or immunosuppressive agents) occurred within 2 years before the start of the study treatment;
-
Has immunodeficiency or received systemic glucocorticoid therapy or any other form of immunosuppressive therapy, and continue to use within 2 weeks of the first administration; 5.Has participated in other anti-tumor drug clinical trials within 4 weeks before the study; 6.According to the judgement of the investigators, there are other factors that may lead to the termination of the study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Sun Yat-sen University Cancer Hospital | Guangzhou | Guangdong | China | 510030 |
Sponsors and Collaborators
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- TQB2450-II-11